Publications by authors named "A D'Hombres"
Article Synopsis
- A study analyzed the occurrence and characteristics of pseudoprogression in high-grade gliomas with isocitrate dehydrogenase mutations (IDHmt HGG), focusing on patients treated with radiotherapy within the French POLA network.
- The research found that 19% of patients experienced pseudoprogression, typically developing asymptomatic contrast-enhanced lesions within 2 years post-treatment, with the occurrence linked to the use of certain chemotherapies (PCV CT).
- The study highlights a concerning trend of misdiagnosis, where 17% of patients with initial true progression may have actually had pseudoprogression, suggesting that careful evaluation is necessary in the early stages post-radiotherapy.
Background: Molecular glioblastomas (i.e. without the histological but with the molecular characteristics of IDH-wild-type glioblastoma) frequently lack contrast enhancement, which can wrongly lead to suspect a lower-grade glioma.
View Article and Find Full Text PDFBackground: Biopsies in patients with a suspected glioma are occasionally nondiagnostic.
Objective: To explore the utility of molecular testing in this setting by determining whether IDH1 and TERT promoter (pTERT) mutations could be detected in nondiagnostic biopsies from glioma patients.
Methods: Using SNaPshot polymerase chain reaction, we retrospectively assessed IDH1 and pTERT mutation status in nondiagnostic biopsies from 28 glioma patients.
Introduction: Currently, no single diagnostic modality allows the distinction between early progression (EP) and pseudo-progression (Psp) in glioblastoma patients. Herein we aimed to identify the characteristics associated with EP and Psp, and to analyze their diagnostic value alone and in combination.
Material And Methods: We reviewed the clinical, conventional magnetic resonance imaging (MRI), and molecular characteristics (MGMT promoter methylation, IDH mutation, and EGFR amplification) of glioblastoma patients who presented an EP (n=59) or a Psp (n=24) within six months after temozolomide radiochemotherapy.
OBJECTIVE Although multimodal treatment for glioblastoma (GBM) has resulted in longer survival, uncertainties exist regarding health-related quality of life and functional performance. Employment represents a useful functional end point and an indicator of social reintegration. The authors evaluated the rate of patients resuming their employment and the factors related to work capacity.
View Article and Find Full Text PDF